pediatric cardiac transplantation present and future · jeffrey gossett, m.d., f.a.a.p....

12
9/4/2018 1 Pediatric Cardiac Transplantation Present and Future Jeffrey Gossett, M.D., F.A.A.P. Director Heart Failure, Heart Transplantation Benioff Children’s Hospitals Disclosure I have no relevant financial relationships with any companies related to the content of this course. Objectives To provide an overview of pediatric cardiac transplantation What is the pediatric population that requires a OHT? How do they do? Describe the changing face of congenital transplantation Shifting single ventricle population Discuss challenges of transplantation for failing Fontans Plastic bronchitis/ Protein losing enteropathy Early phase graft loss Objectives To provide an overview of pediatric cardiac transplantation What is the pediatric population that requires a OHT? How do they do?

Upload: others

Post on 22-Oct-2020

1 views

Category:

Documents


0 download

TRANSCRIPT

  • 9/4/20181

    Pediatric Cardiac TransplantationPresent and FutureJeffrey Gossett, M.D., F.A.A.P.Director Heart Failure, Heart TransplantationBenioff Children’s Hospitals

    Disclosure

    I have no relevant financial relationships with any companies related to the content of this course.

    Objectives

    To provide an overview of pediatric cardiac transplantation

    • What is the pediatric population that requires a OHT?

    • How do they do?

    Describe the changing face of congenital transplantation

    • Shifting single ventricle population

    Discuss challenges of transplantation for failing Fontans

    • Plastic bronchitis/ Protein losing enteropathy

    • Early phase graft loss

    Objectives

    To provide an overview of pediatric cardiac transplantation

    • What is the pediatric population that requires a OHT?

    • How do they do?

  • 9/4/20182

    A nod to history

    First cardiac transplant:• 12/3/1967: Christiaan Barnard - Cape TownFirst infant cardiac transplant

    • 12/6/1967: Adrian Kantrowitz – Brooklyn‒ No immunosuppression

    1984 Loma Linda – Baby Fae• Managed with CSA – died POD #20First successful Neonatal Transplant: November 15, 1985

    • Leonard L. Bailey – Loma Linda, California• Still alive as of 11/17

    So where have we come to?

    ISHLT Annual Report 2017; JHLT 2017 Oct; 36(10) 1037-1079

    0

    100

    200

    300

    400

    500

    600

    700

    Num

    ber o

    f Tra

    nspl

    ants

    11-17

    6-10

    1-5

  • 9/4/20183

    Patients Bridged with Mechanical Circulatory Support

    22.1 21.3 22.5 22.4

    29.4 25.4 26.3

    29.7

    34.8 32.9

    0

    10

    20

    30

    40

    50

    2005 2006 2007 2008 2009 2010 2011 2012 2013 2014

    % o

    f Pat

    ient

    s

    ECMO VAD + ECMO VAD or TAH

    ISHLT Annual Report 2016; JHLT 2016 Oct; 35(10) 1149-1205

    Ventricular Assist Devices- Berlin Heart

    Para-corporeal VAD

    Pulsatile flow

    ‒ Adults think we’re nuts!

    Complication profile is not great

    ‒ Neurologic concerns/strokes

    But it’s what we got!

    Pulsatile outcome (Berlin)

    http://www.uab.edu/medicine/intermacs/images/Federal_Quarterly_Report/Statistical_Summaries/Pedimacs_-_Federal_Partners_Report_2017_Q1.pdf

    Intra-corporeal VAD

    • Continuous flow

    ‒ Standard of care for adults

    Big two are Heartware (HVAD) and Heartmate II

    • Complication profile is dramatically better

    But it’s gotta fit!

    • Almost for sure >40kg

    • Probably 20-40kg (been done down to ~15 kgs)

    Discharge possible!

    Ventricular Assist Devices- Heartware

  • 9/4/20184

    Continuous flow outcomes

    http://www.uab.edu/medicine/intermacs/images/Federal_Quarterly_Report/Statistical_Summaries/Pedimacs_-_Federal_Partners_Report_2017_Q1.pdf

    Outcomes- GRAFT Survival 1982-2015

    ISHLT Annual Report 2017; JHLT 2017 Oct; 36(10) 1037-1079

    0

    25

    50

    75

    100

    0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

    Surv

    ival

    (%)

    Years

  • 9/4/20185

    Outcomes quality of life

    0%

    20%

    40%

    60%

    80%

    100%

    1 Year (N = 2,134) 5 Year (N = 1,415) 10 Year (N = 554)

    No Activity Limitations Performs with Some Assistance Requires Total Assistance

    J Heart Lung Transplant 2008;27: 937-983

    Objectives

    Describe the changing face of congenital transplantation

    • Shifting single ventricle population

    Congenital Heart Disease

    This population is changing

    • Shift from early mortality

    JACC 2010 56(14):1149-57

    Congenital Heart Patients

    ATS 2012; 94:807-16

  • 9/4/20186

    1986-1993n=50(%)

    1994-2001n=116

    (%)

    2002-2009 n=141

    (%)Cardiomyopathy 11/50 (22) 40/116 (34) 70/141 (49)CHD 37/50 (74) 69/116 (60) 67/141 (48)Single V (% of CHD)

    Without palliation 30/37 (81) 33/70 (47) 12/67 (18)After palliation 3/37 (8) 9/70 (13) 16/67 (24)After failed Fontan 1/37 (3) 9/70 (13) 23/67 (34)

    Biventricular CHD 3/37 (8) 17/70 (24) 15/67 (22)Redo transplant 2/50 (4) 7/116 (6) 4/141 (3)

    Congenital Heart Patients

    Increasing incidence of cardiomyopathy??

    ATS 2012; 94:807-16

    1986-1993n=50(%)

    1994-2001n=116

    (%)

    2002-2009 n=141

    (%)Cardiomyopathy 11/50 (22) 40/116 (34) 70/141 (49)CHD 37/50 (74) 69/116 (60) 67/141 (48)Single V (% of CHD)

    Without palliation 30/37 (81) 33/70 (47) 12/67 (18)After palliation 3/37 (8) 9/70 (13) 16/67 (24)After failed Fontan 1/37 (3) 9/70 (13) 23/67 (34)

    Biventricular CHD 3/37 (8) 17/70 (24) 15/67 (22)Redo transplant 2/50 (4) 7/116 (6) 4/141 (3)

    1986-1993n=50(%)

    1994-2001n=116

    (%)

    2002-2009 n=141

    (%)Cardiomyopathy 11/50 (22) 40/116 (34) 70/141 (49)CHD 37/50 (74) 69/116 (60) 67/141 (48)Single V (% of CHD)

    Without palliation 30/37 (81) 33/70 (47) 12/67 (18)After palliation 3/37 (8) 9/70 (13) 16/67 (24)After failed Fontan 1/37 (3) 9/70 (13) 23/67 (34)

    Biventricular CHD 3/37 (8) 17/70 (24) 15/67 (22)Redo transplant 2/50 (4) 7/116 (6) 4/141 (3)

    Congenital Heart Patients

    Shift away from primary transplant for HLHS/single ventricle

    ‒ “Transplantation for heart failure related to failed SV palliation has become the most common indication for patients with CHD”

    ATS 2012; 94:807-16

    1986-1993n=50(%)

    1994-2001n=116

    (%)

    2002-2009 n=141

    (%)Cardiomyopathy 11/50 (22) 40/116 (34) 70/141 (49)CHD 37/50 (74) 69/116 (60) 67/141 (48)Single V (% of CHD)

    Without palliation 30/37 (81) 33/70 (47) 12/67 (18)After palliation 3/37 (8) 9/70 (13) 16/67 (24)After failed Fontan 1/37 (3) 9/70 (13) 23/67 (34)

    Biventricular CHD 3/37 (8) 17/70 (24) 15/67 (22)Redo transplant 2/50 (4) 7/116 (6) 4/141 (3)

    Shifting Single Ventricles

    1986-93: 30/37 without palliation

    • 81 % of CHD and 60% of TOTAL transplant volume!

    1986-1993n=22(%)

    1994-2001n=90(%)

    2002-2009 n=141

    (%)Cardiomyopathy 50 44 49CHD 41 48 48Single V (% of CHD)

    Without palliation 22 16 18After palliation 33 21 24After failed Fontan 11 21 34

    Biventricular CHD 33 40 22

    1986-1993n=50(%)

    1994-2001n=116

    (%)

    2002-2009 n=141

    (%)Cardiomyopathy 22 34 49CHD 74 60 48Single V (% of CHD)

    Without palliation 81 47 18After palliation 8 13 24After failed Fontan 3 13 34

    Biventricular CHD 8 24 22

    • So what happens if we take OUT most of those early HLHS?

    1986-1993n=50(%)

    1994-2001n=116

    (%)

    2002-2009 n=141

    (%)

    THE FUTURE??N=171(%)

    Cardiomyopathy 11/50 (22) 40/116 (34) 70/141 (49) 70/171 (40)CHD 37/50 (74) 69/116 (60) 67/141 (48) 95/171 (56)Single V (% of CHD)

    Without palliation 30/37 (81) 33/70 (47) 12/67 (18) 12/95 (13)After palliation 3/37 (8) 9/70 (13) 16/67 (24) 16/95 (17)After failed Fontan 1/37 (3) 9/70 (13) 23/67 (34) 51/95 (54)

    Biventricular CHD 3/37 (8) 17/70 (24) 15/67 (22) 15/95 (16)

    Future of OHT???

    If we add most of the neonatal palliations back later

    1986-1993n=50(%)

    1994-2001n=116

    (%)

    2002-2009 n=141

    (%)

    THE FUTURE??N=171(%)

    Cardiomyopathy 11/50 (22) 40/116 (34) 70/141 (49) 70/171 (40)CHD 37/50 (74) 69/116 (60) 67/141 (48) 95/171 (56)Single V (% of CHD)

    Without palliation 30/37 (81) 33/70 (47) 12/67 (18) 12/95 (13)After palliation 3/37 (8) 9/70 (13) 16/67 (24) 16/95 (17)After failed Fontan 1/37 (3) 9/70 (13) 23/67 (34) 51/95 (54)

    Biventricular CHD 3/37 (8) 17/70 (24) 15/67 (22) 15/95 (16)

  • 9/4/20187

    Future of OHT??

    Just focusing on the single ventricles then:

    Present of OHT!

    Objectives

    Discuss challenges of transplantation for failing Fontans

    • Plastic bronchitis/ Protein losing enteropathy

    • Early phase graft loss

    The “Failed Fontan”

    Uni-ventricular heart with “heart failure”‒ Different from “typical” adult heart failure Ventricular dysfunction (or NOT) AV valve regurg Arrhythmia Hepatic insufficiency Protein losing enteropathy (PLE) Plastic Bronchitis (PB)

    • They just DON’T fit a box in UNet!

  • 9/4/20188

    Survival after OHT for Failed Fontan

    What do they look like?

    • Multiple prior operations

    • Elevated Panel Reactive Antibody (PRA)

    • Poor nutritional status

    • Multi-organ system dysfunction typical

    Typical point when we meet them!

    OHT for Failed Fontan: Lurie Children’s

    224 Transplants: 1988 – 2013 23 failed Fontan

    • Mean age: 14.9 years (4.4 – 47 years)• Mean interval since Fontan 8.3 yearsMean # Prior operations = 3.7PLE (n = 15)Plastic Bronchitis (n = 2) s/p Fontan Conversion (n = 8)Ventilator (n = 8)

    Ann Thorac Surg 2013; 96:1413-9 Ann Thorac Surg 2013; 96:1413-9

    Results

    5 early deaths (23%)

    • No clear risk factors (likely due to n)

    • Renal failure a concern

    PLE resolved in all survivors

    Plastic Bronchitis resolved in all survivors

    Pulmonary AVMs resolved as well

  • 9/4/20189

    Protein Losing Enteropathy

    Protein loss through from the GI tract

    • In CHD dominantly reported in single ventricle pts after Fontan Etiology unclear

    • ? increased hydrostatic pressure • Non-pulsatile flow?• Altered cardiac output

    Seen despite “optimal” Fontan hemodynamics• With preserved and decreased function

    Many potential treatments described• Historically significant mortality/morbidity

    PHTS PLE Project

    Compared transplantation after Fontan with vs without PLE• 96 patients with PLE vs 260 without• Patients with PLE were:

    ‒ Older (12.2 vs 8.7yrs)‒ Larger (BSA 1.1 vs 0.9m2)‒ Lower serum Bili (0.5 vs. 0.9mg/dl)‒ Lower BNP (59 vs 227pg/ml)‒ Lower Albumin (2.7 vs 3.8 gm/dl)‒ Lower PCW (10.5 vs 14mmHg)‒ Less PB (9.1 vs 26.1%)‒ Less intubation (3.1 vs 13.1%)

    Schumacher, Gossett et al J Heart Lung Tx 2015; 34:1169-76

    PHTS PLE Project

    Schumacher, Gossett et al J Heart Lung Tx 2015; 34:1169-76

    Plastic Bronchitis

    Formation of occlusive airway casts

    • In CHD dominantly reported in single ventricle pts after Fontan

    Etiology/treatment unclear

  • 9/4/201810

    PHTS Plastic Bronchitis project

    Multicenter prospective database in pediatric OHT

    • Captures ~85% of peds OHT

    10/35 centers had patients with PB

    • 14 TOTAL patients

    10 patients underwent OHT

    • Early mortality was higher

    • Conditional (after 30 d) and late (to 5 year) survival was equivalent

    Plastic Bronchitis resolved in ALL survivors

    • Same shown repeatedly for PLE

    Gossett et al. JACC 2013;61:985-986

    PHTS Plastic Bronchitis project

    Gossett et al. JACC 2013;61:985-986

    Survival after OHT for Failed Fontan

    Bernstein et al Circ 2006; 114:273-80

    Current Era

    Simpson et al ATS 2017; 103:1315-21

  • 9/4/201811

    ACHD vs non-CHD

    Bryant and Morales Ann Cardiothorac Surg 2018;7(1):143-151 based on Doumouras et al J Heart Lung Transplant 2016;35:1337–1347

    Supporting the SV to OHT

    All of our outcomes are hurt by early phase mortality

    • Earlier referral

    ‒ Better listing concepts/criteria

    • Better prediction and prevention of comorbidities

    Better options for reversing end organ injury through support?

    Supporting the SV to OHT

    VAD support for the SV

    • Very limited numbers

    ‒ ~15-20% of Pedimacs implants for SV overall *

    ‒ ~5% for Fontan *

    • Devices applied:

    ‒ Heartware (systemic); TAH; Jarvik VAD (FTN); Berlin (FTN, systemic); Heartmate; Tandem (systemic)

    ‒ Certainly others!

    Mortality and morbidity too high– We MUST do better!

    * Pedimacs unpublished communications

    Conclusions

    World wide OHT numbers are relatively static

    • Organ availability must increase

    Longer waiting times mitigated by improved medical therapies

    • VAD therapies in pediatrics lag far behind adult counterparts

    More congenital patients will be coming!

    • Higher up front mortality, but better long term!

    • Single ventricle patients are challenging, but will be the future

    • We must find better support options to maximize outcomes

  • 9/4/201812

    Remind me why we do this???

    http://www.nytimes.com/2009/08/12/us/12huesman.html?_r=1&ref=health

    Thank you!

    [email protected](773) 612-4104